How Alzheimer's drug breakthrough opens door for two MORE experimental therapies
Lecanemab was found to slow the progress of Alzheimer's by a quarter - putting an end to decades of failed trials. It has reignited hopes targeting amyloid beta plaque is the key to treating the disease.